FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Nastech hit on missed payment; Nastech announces Phase I data;and much more...

Tools

> Shares of Nastech Pharmaceuticals took a beating yesterday after P&G failed to make a scheduled $15 million payment in 2006. The two companies are collaborating on a nasal spray for osteoporosis. Report

> Today Nastech announced positive Phase I data on its insulin nasal spray. Release

> Solvay and Wyeth Pharmaceuticals are touting new Phase II and III data which supports the efficacy of its antipsychotic drug bifeprunox in comparison with a placebo. Report

> Tucson-based ImaRX has pulled its IPO, citing weak market conditions. Report

> Canada's ProMetic Life Sciences has pulled its IPO as well, saying that higher 2007 revenue will make the company worth more than it could expect from a public float. Report

> Migenix has raised $11.6 million in bought-deal financing. Release

And Finally... In a small number of cases, parents are using genetic screening to select embryos with defects like their own. Article

More stories about Wyeth   Stem cells   Solvay Pharmaceuticals   Phase II   osteoporosis   nasal spray   insulin   Biotech IPO  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.